azacitidine celgene
celgene europe bv - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiska medel - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.
azacitidine stada 25 mg/ml pulver till injektionsvätska, suspension
stada arzneimittel ag - azacitidin - pulver till injektionsvätska, suspension - 25 mg/ml - mannitol hjälpämne; azacitidin 25 mg aktiv substans
azacitidine zentiva 25 mg/ml pulver till injektionsvätska, suspension
zentiva k.s. - azacitidin - pulver till injektionsvätska, suspension - 25 mg/ml - mannitol hjälpämne; azacitidin 25 mg aktiv substans
azacitidine sandoz 25 mg/ml pulver till injektionsvätska, suspension
sandoz a/s - azacitidin - pulver till injektionsvätska, suspension - 25 mg/ml - azacitidin 25 mg aktiv substans; mannitol hjälpämne
azacitidine tillomed 25 mg/ml pulver till injektionsvätska, suspension
tillomed pharma gmbh - azacitidin - pulver till injektionsvätska, suspension - 25 mg/ml - mannitol hjälpämne; azacitidin 25 mg aktiv substans
azacitidine ever pharma 25 mg/ml pulver till injektionsvätska, suspension
ever valinject gmbh - azacitidin - pulver till injektionsvätska, suspension - 25 mg/ml - mannitol hjälpämne; azacitidin 25 mg aktiv substans
onureg
bristol-myers squibb pharma eeig - azacitidin - leukemi, myeloid, akut - antineoplastiska medel - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).
azacitidine glenmark 25 mg/ml pulver till injektionsvätska, suspension
glenmark arzneimittel gmbh - azacitidin - pulver till injektionsvätska, suspension - 25 mg/ml - azacitidin 25 mg aktiv substans; mannitol hjälpämne
azacitidine sun 25 mg/ml pulver till injektionsvätska, suspension
sun pharmaceutical industries europe b.v. - azacitidin - pulver till injektionsvätska, suspension - 25 mg/ml - mannitol hjälpämne; azacitidin 25 mg aktiv substans
azacitidine lorien 25 mg/ml pulver till injektionsvätska, suspension
laboratorios lorien s.l. - azacitidin - pulver till injektionsvätska, suspension - 25 mg/ml - azacitidin 25 mg aktiv substans; mannitol hjälpämne